47% of First Cardiac Events Happen in

Describe the continuum from insulin resistance and prediabetes to overt type 2 diabetes

Recognize hyperinsulinemia as a primary driver of cardiometabolic risk

Identify common clinical patterns of dysglycemia including postprandial glucose abnormalities

Apply pattern-based interpretation of glucose and insulin markers

Recognize fatty liver disease as a central driver of cardiometabolic risk rather than an isolated hepatic condition

Interpret liver enzymes within the broader context of metabolic, lipid, and glucose abnormalities

Identify patients with discordant laboratory findings in whom cardiometabolic risk may be underestimated

Apply practical risk stratification strategies to determine when further evaluation or escalation of workup for fatty liver disease is warranted

Apply a cardiometabolic framework to the clinical assessment of coronary artery disease (CAD) and atherosclerotic cardiovascular disease (ASCVD)

Explain the metabolic contributions to heart failure with preserved ejection fraction (HFpEF) and identify patient characteristics in which this framework is most clinically relevant

Recognize cardiovascular symptoms and red flags that warrant urgent evaluation or escalation of care within a cardiometabolic risk context

Describe key components of cardiometabolic optimization for patients with established cardiovascular disease, including lifestyle, metabolic, and risk-modifying strategies

Recognize cardiometabolic dysfunction as a shared systems driver across reproductive, metabolic, and chronic disease states

Identify key clinical conditions (e.g., PCOS, obesity, osteoporosis, cancer) as manifestations of underlying metabolic dysfunction

Describe the role of insulin resistance, adipose dysfunction, and inflammation in cross-system disease development

Apply a systems-based lens to prioritize metabolic drivers when evaluating complex, multi-system presentations

Compare mechanisms for key pharmacotherapies: metformin, GLP-1 RAs, dual incretin therapies, SGLT2 inhibitors

Apply high-level decision rules to lipid-lowering therapies—statins, ezetimibe, niacin, PCSK9 inhibitors, and bempedoic acid—based on cardiometabolic risk profiles

Identify first-line antihypertensive medication classes and distinguish metabolically neutral or favorable options in patients with cardiometabolic dysfunction

Recognize common medication-related adverse effects that may impair metabolic progress, adherence, or quality of life

Implement evidence-informed strategies to mitigate medication-related side effects while maintaining therapeutic benefit.

Integrate pharmacologic therapy with lifestyle and nutritional interventions using a complementary—not either/or—approach to cardiometabolic care

Compare LDL-cholesterol, non-HDL cholesterol, and apolipoprotein B (ApoB) as markers of atherogenic lipoprotein burden and ASCVD risk

Explain the role of triglyceride-rich lipoproteins and remnant cholesterol in residual cardiovascular risk

Identify lipid patterns associated with insulin resistance, including increased particle burden despite “normal” LDL-C levels

Summarize key principles of atherosclerosis pathophysiology relevant to clinical risk assessment and management

Differentiate patients who may benefit from aggressive lipid-lowering strategies from those appropriate for a more conservative, risk-based approach

Explain the metabolic mechanisms contributing to hypertension, including the roles of insulin resistance, sympathetic nervous system activation, the renin–angiotensin–aldosterone system (RAAS), and altered sodium handling

Describe how endothelial dysfunction and arterial stiffness contribute to blood pressure elevation and vascular risk

Identify secondary or contributing factors to hypertension that warrant further evaluation in patients with cardiometabolic dysfunction

Interpret blood pressure measurements using home readings and ambulatory patterns to distinguish white coat hypertension, masked hypertension, and sustained hypertension

Apply a cardiometabolic framework to blood pressure assessment to inform appropriate monitoring and management strategies

Describe how key gut-derived metabolites—including bile acids, short-chain fatty acids (SCFAs), and trimethylamine N-oxide (TMAO)—influence cardiometabolic physiology

Explain the role of intestinal permeability and gut-driven inflammation as amplifiers of cardiometabolic risk

Identify nutrition and dietary strategies that favorably modify gut-derived cardiometabolic signaling pathways

Differentiate clinical scenarios in which gut-focused interventions meaningfully support cardiometabolic outcomes from those in which they are unlikely to add value

Integrate gut-related mechanisms into a balanced, evidence-informed cardiometabolic care strategy

Explain the clinical relevance of mitochondrial function and metabolic flexibility in cardiometabolic health and disease

Describe key intersections between hormone signaling—including thyroid function, stress physiology (cortisol), and sex hormones—and cardiometabolic risk

Discuss how sleep quality and circadian rhythm disruption influence metabolic regulation, insulin sensitivity, and cardiovascular risk

Identify environmental exposures, including endocrine-disrupting chemicals, that may contribute to cardiometabolic dysfunction

Integrate functional drivers such as mitochondrial health, hormonal balance, circadian alignment, and environmental inputs into a comprehensive cardiometabolic assessment framework

Identify dietary patterns with the strongest evidence for improving cardiometabolic outcomes

Apply practical nutrition strategies—including protein and fiber timing, glycemic control, and meal sequencing—to support metabolic health

Differentiate physical activity modalities (resistance training, walking, zone 2 aerobic activity) based on their relative impact on cardiometabolic risk

Prescribe sleep and stress interventions as clinical tools to support metabolic and cardiovascular health

Utilize minimal effective dose frameworks to design realistic, sustainable nutrition and lifestyle interventions

Evaluate the appropriate role of wearable technology in monitoring and supporting cardiometabolic behavior change

Identify common cardiometabolic medications associated with drug-induced nutrient depletion (DIND) and determine when targeted nutrient repletion is clinically appropriate

Explain the adjunctive role of nutraceuticals in supporting cardiometabolic pathways alongside lifestyle and pharmacologic therapy, rather than as standalone treatment

Apply a pattern-driven approach to nutraceutical selection by matching interventions to dominant cardiometabolic patterns such as insulin resistance, dyslipidemia, hypertension, and fatty liver disease

Describe the primary mechanisms of action for selected evidence-based nutraceuticals that influence insulin signaling, lipid metabolism, vascular function, and hepatic health

Integrate nutraceutical strategies into comprehensive cardiometabolic care plans using an evidence-informed, risk-appropriate framework.